The Future of 
Vascular Bio-Technology


Integene's gene-therapy technology represents a platform development program capable of addressing several multi-billion dollar indications, such as peripheral artery disease (PAD), coronary artery disease (CAD), retinopathy, chronic wounds, and other vascular disorders.

Because of the large unmet medical need, the Integene team is focusing first on end-stage critical limb ischemia (CLI), a condition which has no current effective pharmacologic treatment.

End-Stage Critical Limb Ischemia (CLI)

Atherosclerosis is a disease in which plaque builds up on the artery walls blocking blood flow. This condition is caused by poor diet, genetic factors, and lack of exercise.

Critical limb ischemia (CLI) is a subset of a common condition known as Peripheral Artery Disease (PAD), which is the narrowing of peripheral arteries due to atherosclerosis, and is most common in the arteries leading to the pelvis and legs.   CLI is similar to coronary artery disease (CAD) which restricts blood flow to the heart.  More than 10 million Americans and over 50 million people worldwide suffer from PAD. 

The end-stage of CLI is a serious condition with no long-term reliable cure for the disease. Various treatments are being tried. In some cases, widening of the arteries (angioplasty) or a stent inserted into the blockage may bring temporary relief. These treatments however, generally require the use of blood thinners with poor long-term outcomes.  CLI often requires the removal (amputation) of all or part of the affected lower limb, and generally leads to rapid morbidity.  There are about 150,000 amputations performed annually in the U.S. every year due to end-stage CLI.    

Website Builder